Subtype
Pancreatic Neoplasm
CI-CAN-00001356Explore in graph →
Non-malignant988 active trials8 approved drugs63 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001356Explore in graph →
Clinical trials
4,217 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05795920 | Utidelone Injection Combined With Gemcitabine in First-line Chemotherapy for Unresectable Advanced Pancreatic Cancer | unknown | Phase 2 | 92 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | Apr 3, 2023 | clinicaltrials |
| NCT05616494 | A Study of Docetaxel for Injection (Albumin-bound) in Patients With Pancreatic Cancer | unknown | Phase 2 | 53 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 |
| Mar 22, 2023 |
| clinicaltrials |
| NCT04289792 | Split-course SBRT for Borderline Resectable and Locally Advanced Pancreatic Cancer | unknown | Phase 2 | 27 | Fujian Medical University Union HospitalOTHER | 1 | Feb 16, 2023 | clinicaltrials |
| NCT05679050 | Phase II Study on Sequential AG and FOLFIRINOX as Neoadjuvant Therapy in Patients With Resectable Pancreatic Cancer | unknown | Phase 2 | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jan 10, 2023 | clinicaltrials |
| NCT05641233 | Preoperative Radiotherapy in Patients at High Risk of Postoperative Pancreatic Fistula After Pancreatoduodenectomy(FIBROPANC-1) | unknown | Phase 1 / Phase 2 | 33 | Erasmus Medical CenterOTHER | 1 | Dec 7, 2022 | clinicaltrials |
| NCT05634564 | Concurrent Chemoradiotherapy Combined With Immunotherapy in Patients With Potentially Resectable Pancreatic Cancer | unknown | Phase 2 | 62 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 1 | Dec 5, 2022 | clinicaltrials |
| NCT05627427 | Multi-cohort Study of Surufatinib Plus Sintilimab in Metastatic NEN and Pancreatic Carcinoma Who Failed Standard Chemotherapy | unknown | Phase 2 | 60 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Nov 25, 2022 | clinicaltrials |
| NCT05587088 | Evaluation of the Safety and Efficacy of Esperanza Extract (PA001)(PA001) | unknown | Phase 1 / Phase 2 | 82 | Hospital Universitario San IgnacioOTHER | 1 | Oct 19, 2022 | clinicaltrials |
| NCT05566743 | A Study Evaluating Maintenance Therapy After First Line Chemotherapy in Metastatic Cancer Pancreas | unknown | Phase 2 | 40 | Menoufia UniversityOTHER | 1 | Oct 4, 2022 | clinicaltrials |
| NCT03487016 | First-line Therapy in Metastatic PDAC(FOOTPATH) | unknown | Phase 2 | 270 | Ludwig-Maximilians - University of MunichOTHER | 1 | Sep 8, 2022 | clinicaltrials |
| NCT04398446 | Effect of Hemp-CBD on Patients With CIPN(Coala-T-CBD) | unknown | Phase 2 | 56 | Main Line HealthOTHER | 1 | Sep 1, 2022 | clinicaltrials |
| NCT05181605 | Survival Analysis After Neoadjuvant Therapy in Patients With Resectable Pancreatic Cancer and Risk Factors | unknown | Phase 2 / Phase 3 | 116 | Instituto de investigación e innovación biomédica de CádizOTHER | 1 | Aug 9, 2022 | clinicaltrials |
| NCT04418739 | Intravenous Human Albumin In Improving Pancreaticoduodenectomy Outcomes | unknown | Phase 2 | 122 | Universiti Kebangsaan Malaysia Medical CentreOTHER | 1 | Jun 16, 2022 | clinicaltrials |
| NCT05399394 | Induction FOLFIRINOX Followed by Chemoradiation in Locally Advanced Pancreatic Cancer(FOLRT) | unknown | Phase 2 | 50 | Campus Bio-Medico UniversityOTHER | 0 | Jun 1, 2022 | clinicaltrials |
| NCT02839343 | Combination Chemotherapy With or Without Hypofractionated Radiation Therapy Before Surgery in Treating Patients With Pancreatic Cancer | unknown | Phase 2 | 126 | Alliance for Clinical Trials in OncologyOTHER | 2 | May 24, 2022 | clinicaltrials |
| NCT05327582 | An Open-label, Phase I/II Study of PLENA Regimen in Patients With Unresectable Pancreatic Cancer or BTC | unknown | Phase 1 / Phase 2 | 65 | Chinese PLA General HospitalOTHER | 1 | Apr 14, 2022 | clinicaltrials |
| NCT05298020 | Envafolimab Combined With Endostar and Chemotherapy for First-line Treatment of Advanced Pancreatic Cancer | unknown | Phase 2 | 20 | The Affiliated Hospital of Xuzhou Medical UniversityOTHER | 1 | Mar 28, 2022 | clinicaltrials |
| NCT04835402 | Electroporation Potentiated Immunotherapy in Cancer(EPIC-1) | unknown | Phase 2 | 8 | Ole Thorlacius-Ussing, MD, DMSc, Professor of SurgeryOTHER | 1 | Mar 9, 2022 | clinicaltrials |
| NCT05162118 | Clinical Study of VG161 in Combination With Nivolumab in Subjects With Advanced Pancreatic Cancer | unknown | Phase 1 / Phase 2 | 51 | Zhejiang UniversityOTHER | 1 | Mar 9, 2022 | clinicaltrials |
| NCT05257122 | A Phase II Clinical Trial of Fruquintinib as Third Line Treatment in Advanced Pancreatic Cancer | unknown | Phase 2 | 32 | Fudan UniversityOTHER | 1 | Feb 25, 2022 | clinicaltrials |
| NCT03221400 | PEN-866 in Patients With Advanced Solid Malignancies | unknown | Phase 1 / Phase 2 | 340 | Tarveda TherapeuticsINDUSTRY | 1 | Feb 17, 2022 | clinicaltrials |
| NCT05168527 | The First Line Treatment of Fruquintinib Combined With Albumin Paclitaxel and Gemcitabine in Pancreatic Cancer Patients | unknown | Phase 2 | 30 | Fudan UniversityOTHER | 1 | Jan 14, 2022 | clinicaltrials |
| NCT05185869 | SHR6390 Plus Nab-paclitaxel and Gemcitabine in Advanced/Metastatic Pancreatic Cancer | unknown | Phase 2 | 58 | Ruijin HospitalOTHER | 1 | Jan 11, 2022 | clinicaltrials |
| NCT04652206 | Clinical Trial to Investigate Safety, Tolerability and MTD for SCO-101 in Combination With Gemcitabine and Nab-paclitaxel in Inoperable Pancreatic Cancer Patients.(PANTAX-Ib) | unknown | Phase 1 / Phase 2 | 18 | Scandion Oncology A/SINDUSTRY | 2 | Dec 29, 2021 | clinicaltrials |
| NCT05143151 | CD276-targeted Chimeric Antigen Receptor T Cells in Treatment With Advanced Pancreatic Cancer(CAR-T) | unknown | Phase 1 / Phase 2 | 10 | Shenzhen University General HospitalOTHER | 1 | Dec 3, 2021 | clinicaltrials |
| NCT05138159 | A Study of Donafenib Plus S-1 in Treating Patients With Metastatic Pancreatic Cancer After Chemotherapy With Nab-paclitaxel Plus Gemcitabine Regimen | unknown | Phase 2 | 10 | Fudan UniversityOTHER | 1 | Nov 30, 2021 | clinicaltrials |
| NCT05100329 | A Study of Mitoxantrone Hydrochloride Liposome Injection in Patients With Advanced Pancreatic Cancer | unknown | Phase 2 | 38 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 0 | Oct 29, 2021 | clinicaltrials |
| NCT04089150 | MFOLFIRINOX And Stereotactic Radiotherapy (SBRT) for Pancreatic Cancer With High Risk and Locally Advanced Disease(MASTERPLAN) | unknown | Phase 2 | 120 | Australasian Gastro-Intestinal Trials GroupNETWORK | 1 | Oct 22, 2021 | clinicaltrials |
| NCT05066802 | A Phase 2 Trial of Neoadjuvant Modified FOLFIRINOX Chemotherapy for Resectable Pancreatic Adenocarcinoma | unknown | Phase 2 | 27 | Yonsei UniversityOTHER | 1 | Oct 4, 2021 | clinicaltrials |
| NCT04718701 | Anlotinib, Toripalimab and Nab-paclitaxel in Locally Advanced/Metastatic Pancreatic Cancer(ATNPA) | unknown | Phase 2 | 53 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Aug 16, 2021 | clinicaltrials |
| NCT02305186 | Safety and Immunological Effect of Pembrolizumab in Resectable or Borderline Resectable Pancreatic Cancer(UVA-PC-PD101) | unknown | Phase 1 / Phase 2 | 68 | Craig L Slingluff, JrOTHER | 1 | Aug 13, 2021 | clinicaltrials |
| NCT03528785 | A Study of Nal-IRI With 5-FU, Levofolinic Acid and Oxaliplatin in Patients With Resectable Pancreatic Cancer(nITRo) | unknown | Phase 2 | 67 | Centro Ricerche Cliniche di VeronaOTHER | 1 | Aug 2, 2021 | clinicaltrials |
| NCT01676259 | A Phase 2 Study of siG12D LODER in Combination With Chemotherapy in Patients With Locally Advanced Pancreatic Cancer(PROTACT) | unknown | Phase 2 | 80 | Silenseed LtdINDUSTRY | 2 | Jul 2, 2021 | clinicaltrials |
| NCT04907864 | Effect of Multi-modal Intervention Care on Cachexia in Patients With Advanced Cancer Compared to Conventional Management (MIRACLE)(MIRACLE) | unknown | Phase 2 | 112 | Kil Yeon LeeOTHER | 1 | Jun 1, 2021 | clinicaltrials |
| NCT04814485 | Efficacy and Safety of SHR-1020 Combined With Albumin-bound Paclitaxel in the Second-line Treatment of Pancreatic Cancer | unknown | Phase 2 | 39 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | May 25, 2021 | clinicaltrials |
| NCT03959150 | Metronomic Chemotherapy With Capecitabine for Pancreatic Cancer | unknown | Phase 2 / Phase 3 | 231 | Ruijin HospitalOTHER | 1 | Apr 30, 2021 | clinicaltrials |
| NCT04808687 | Neoadjuvant Nab-Paclitaxel and S-1 in Resectable Pancreatic Cancer | unknown | Phase 2 | 72 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Mar 22, 2021 | clinicaltrials |
| NCT04739046 | An Exploratory Trial to Evaluate Efficacy and Safety for Combination Treatment of Adenovirus Double Suicide Gene Therapy | unknown | Phase 2 | 12 | Seoul National University Bundang HospitalOTHER | 1 | Mar 17, 2021 | clinicaltrials |
| NCT03374293 | Combination of Radiation Therapy and Anti-PD-1 Antibody in Treating Patients With Pancreatic Cancer | unknown | Phase 2 | 21 | Shixiu WuOTHER | 1 | Feb 10, 2021 | clinicaltrials |
| NCT04723030 | The Transformation of Locally Advanced Pancreatic Cancer. | unknown | Phase 2 | 30 | Peking UniversityOTHER | 1 | Jan 25, 2021 | clinicaltrials |
| NCT03986294 | Second Line Treatment With Nal-IRI and S1 in Pancreatic Cancer(NAPAN) | unknown | Phase 2 | 122 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)OTHER | 1 | Jan 15, 2021 | clinicaltrials |
| NCT03989310 | An Open-label, Phase I/II Study of the Pan-immunotherapy in Patients With Local Advanced/Metastatic Pancreatic Cancer | unknown | Phase 1 / Phase 2 | 50 | Chinese PLA General HospitalOTHER | 1 | Dec 23, 2020 | clinicaltrials |
| NCT04183478 | The Efficacy and Safety of K-001 in the Treatment of Advanced Pancreatic Cancer | unknown | Phase 2 / Phase 3 | 600 | RenJi HospitalOTHER | 1 | Nov 12, 2020 | clinicaltrials |
| NCT02896803 | Fluorouracil and Oxaliplatin as First-line for Advanced Pancreatic Cancer(PanFLOX) | unknown | Phase 2 | 37 | Instituto do Cancer do Estado de São PauloOTHER | 1 | Nov 10, 2020 | clinicaltrials |
| NCT04581876 | The Safety and Efficacy of the Combination of Raltitrexed for Injection and Nab-Paclitaxel in Advanced Pancreatic Cancer | unknown | Phase 2 | 120 | Fudan UniversityOTHER | 1 | Oct 9, 2020 | clinicaltrials |
| NCT04571489 | A Phase II Study of Gimatecan (ST1481) in Locally Advanced or Metastatic Pancreatic Cancer | unknown | Phase 2 | 60 | Lee's Pharmaceutical LimitedINDUSTRY | 1 | Oct 1, 2020 | clinicaltrials |
| NCT02717091 | Neoadjuvant FOLFIRINOX or Nab-paclitaxel With Gemcitabine for Borderline Resectable Pancreatic Cancer | unknown | Phase 2 | 50 | Nagoya UniversityOTHER | 0 | Sep 10, 2020 | clinicaltrials |
| NCT04520386 | OMT-111 for Terminal Stage Solid Tumors | unknown | Phase 2 | 78 | MetiMedi PharmaceuticalsINDUSTRY | 1 | Sep 9, 2020 | clinicaltrials |
Data updated 23 days agoSource updated Apr 3, 2023source: clinicaltrials